Study of human protein C concentrate for protein C deficiency
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is studying a medication called TAK-662 (freeze-dried human protein C concentrate) in people with congenital protein C deficiency. The goal is to see how well it works and how safe it is for patients who need this replacement therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a rare inherited condition called congenital protein C deficiency.
- You are already receiving or will be receiving the study treatment (TAK-662).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
This early study tests a new type of protein replacement therapy for healthy volunteers. The purpose is to see if it is safe and how the body handles it.
This study reviews medical records of people with a rare blood clotting disorder called cTTP who received a treatment called rADAMTS13 through an early access program. The goal is to learn more about how the treatment works in real life.
This study tests a new medicine called TTI-0102 for cystinosis. It aims to see if it can help manage cystine levels in the body, which may reduce kidney and other organ damage.
This trial is creating a research database for people with severe ADAMTS13 deficiency, a condition where the body has very low activity of a key blood-protein. It may help researchers better understand the condition by collecting and organizing patient information.
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
Hear when a new Protein C Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.